Organization
Yonesi University College of Medicine
5 abstracts
Abstract
A multicenter phase II study of modified FOLFIRINOX for first-line treatment for advanced urachal cancer (ULTMA; KCSG GU20-03).Org: Yonesi University College of Medicine, Yangsan Si, South Korea, Daejeon, South Korea,
Abstract
Additional prognostic value of the BCT score in patients with ER+HER2- breast cancer receiving 21-gene assay–guided adjuvant treatments.Org: Gangnam Severance Hospital, Yonesi University College of Medicine, Seoul National University Hospital, Asan Medical Center, Center for Breast Cancer,
Abstract
Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial).Org: Department of Surgery, Brigham and Women's Hospital, Boston, MA, Seoul National University College of Medicine, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Seoul National University Hospital, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Prospective single-arm study of endocrine therapies with ovarian function suppression in premenopausal patients with node-positive early breast cancer with low genomic risk (INTERSTELLAR trial, KBCSG-25).Org: Gangnam Severance Hospital, Yonesi University College of Medicine, Gangnam-Gu, Nacuity Pharmaceuticals, Korea United Pharmaceuticals Inc.,
Abstract
Sustained prognostic impact of primary tumor characteristics on long-term (overall) survival after distant metastasis in young ER+ HER2- breast cancer.Org: Department of Surgery, Brigham and Women's Hospital, Boston, MA, Dongtan Sacred Heart Hospital, Hallym University, Seoul National University College of Medicine, Samsung Medical Center,